Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood...

Area of Science:

• Pediatric Pulmonology
• Asthma Management
• Pharmacotherapy

Background:

• Mild persistent childhood asthma requires effective treatment strategies.
• Inhaled corticosteroids (ICS) like budesonide are a cornerstone of asthma management.
• Comparing daily versus as-needed ICS dosing is crucial for optimizing treatment outcomes and minimizing side effects.

Purpose of the Study:

• To compare the efficacy of daily inhaled budesonide versus as-needed budesonide in managing mild persistent childhood asthma.
• To evaluate the impact of different budesonide dosing regimens on lung function, asthma exacerbations, and growth in children.
• To assess the effectiveness of disodium cromoglycate (DSCG) as a comparator treatment.

Main Methods:

• A randomized controlled trial involving 176 children aged 5-10 years with newly diagnosed asthma.
• Three treatment groups: continuous budesonide, as-needed budesonide, and disodium cromoglycate (DSCG).
• Assessment of lung function, exacerbation frequency, and growth velocity over 18 months.

Main Results:

• Continuous budesonide initially improved lung function and reduced exacerbations compared to DSCG, with a minor impact on growth velocity.
• After 18 months, lung function improvements were similar across groups.
• Continuous budesonide resulted in significantly fewer exacerbations during months 7-18 compared to as-needed budesonide or DSCG.
• As-needed budesonide therapy was associated with catch-up growth.

Conclusions:

• Regular budesonide use provides superior asthma control but may have more systemic effects than as-needed use.
• ICS dosage can be reduced once asthma is controlled.
• Some children with mild persistent asthma may not require continuous ICS treatment.